Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis

ClinicalTrials.gov ID: NCT04212169

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04212169. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects With Moderate-to-severe Atopic Dermatitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult subjects with Atopic Dermatitis.

Study identification

NCT ID: NCT04212169
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: AstraZeneca; Industry
Enrollment: 148 participants

Conditions and interventions

Conditions

Atopic Dermatitis

Interventions

MEDI3506 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 9, 2019 (Actual)
Primary completion: Jul 21, 2022 (Actual)
Completion: Sep 20, 2022 (Actual)
Last update posted: Sep 28, 2023

2019 – 2022

United States locations

U.S. sites: 13
U.S. states: 10
U.S. cities: 12

Facility	City	State	ZIP	Site status
Research Site	Birmingham	Alabama	35209	—
Research Site	Santa Monica	California	90404	—
Research Site	Jacksonville	Florida	32256	—
Research Site	Miami	Florida	33180	—
Research Site	Orlando	Florida	32806	—
Research Site	Baton Rouge	Louisiana	70808	—
Research Site	Charlotte	North Carolina	28277	—
Research Site	Tulsa	Oklahoma	74136	—
Research Site	Providence	Rhode Island	02903	—
Research Site	Spartanburg	South Carolina	29303	—
Research Site	Memphis	Tennessee	38119	—
Research Site	San Antonio	Texas	78213	—
Research Site	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04212169, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 28, 2023 · Synced Nov 12, 2026